α-Lipoic Acid Protects Against Ischemia-Reperfusion Injury in Simultaneous Kidney-Pancreas Transplantation

Ambrosi, Nella; Arrosagaray, V.; Guerrieri, Diego; Uva, Pablo; Petroni, J.; Herrera, Monica; Iovanna, Juan; León, Ángel Dámaso Luis; Incardona, Claudio; Chuluyan, Eduardo; Casadei, Domingo

doi:10.1097/tp.0000000000000981

Cited by 43 publications

(29 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are consistent with our previous work . We showed that ALA treatment to the donor and the recipient have better short‐term outcomes than those where only the transplant recipient was treated with ALA .…”

Section: Discussionsupporting

confidence: 93%

α-lipoic acid reduces postreperfusion syndrome in human liver transplantation - a pilot study

et al. 2018

Self Cite

View full text Add to dashboard Cite

A double-blind randomized controlled trial was performed to compare the safety and efficacy of α-lipoic acid (ALA) in liver transplantation (LT). The grafts were randomized to receive ALA or placebo before the cold ischemia time. Furthermore, patients transplanted with the ALA-perfused graft received 600 mg of intravenous ALA, while patients with the nonperfused graft received the placebo just before graft reperfusion. Hepatic biopsy was performed 2 h postreperfusion. Blood samples were collected before, during and 1 and 2 days after reperfusion. Quantitative polymerase chain reaction (qPCR) analysis was performed on biopsies to assess genes involved in the response to hypoxia, apoptosis, cell growth, survival and proliferation, cytokine production and tissue damage protection. Nine of 40 patients developed postreperfusion syndrome (PRS), but seven of them belonged to the control group. There was a decrease in PHD2 and an increase in alpha subunit of hypoxia-inducible factor-1 (HIF-1α) and baculoviral IAP repeat containing 2 (Birc2) transcript levels in the biopsies from the ALA-treated versus the control group of patients. Additionally, plasma levels of alarmins were lower in ALA-treated patients than control patients, which suggests that ALA-treated grafts are less inflammatory than untreated grafts. These results showed that ALA is safe for use in LT, induces gene changes that protect against hypoxia and oxidative stress and reduces the appearance of PRS.

show abstract

Section: Discussionsupporting

confidence: 93%

α-lipoic acid reduces postreperfusion syndrome in human liver transplantation - a pilot study

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…For instance, preconditioning or postconditioning with ALA is protective against I/RI-induced cardiac dysfunction, retinal damage, ovarian torsion injury and reperfusioninduced renal failure [25][26][27][28]. The latest clinical research has uncovered that the protective mechanisms of ALAP against simultaneous kidney-pancreas transplantation-induced renal dysfunction and post-transplant pancreatitis occur through its anti-inflammatory effects [29]. In our study, ALAP decreased the content of TNF-α and IL-6 and increased the content of IL-10 in rat brains, providing further evidence that the neuroprotective effects of ALAP against cerebral I/RI may be closely related to the synergistic inhibition of the inflammatory response and oxidative stress.…”

Section: Discussionmentioning

confidence: 99%

Alpha-Lipoic Acid Preconditioning and Ischaemic Postconditioning Synergistically Protect Rats from Cerebral Injury Induced by Ischemia and Reperfusion Partly via Inhibition TLR4/MyD88/ NF-κB Signaling Pathway

Zhang

Fan

Zhang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: A combination of alpha-lipoic acid preconditioning (ALAP) and ischaemic preconditioning (IPC) has not been tested in an in vivo rat cerebral ischaemia/reperfusion injury (I/RI) model, and the potential protective mechanisms have not been well elucidated. The aim of this study was to investigate the role of the TLR4/ MyD88/ NF-κB signaling pathway in the synergistically neuroprotective and anti-inflammatory effects of ALAP and IPC. Methods: One hundred and fifty male Sprague-Dawley rats, weighing 180-230 g, were randomly divided into the following 5 groups: 1) sham-operated control; 2) I/R; 3) I/R+ALAP; 4) I/R+IPC; 5) I/R+IPC+ALAP. After 2 h of reperfusion, the infarct size, neurological deficit scores, brain oedema, oxidative stress, and inflammatory and apoptotic biomarkers were assessed. In addition, reactive oxygen species (ROS) and cell apoptosis were detected by DHE staining and TUNEL staining, respectively. Results: Both ALAP and IPC treatment attenuated the I/RI-induced neuronal injury, reflected by reductions in the infarct size, neurological deficit scores, brain oedema, lactate dehydrogenase (LDH) release and the inflammatory response, as well as decreased HMGB1, TLR4, MyD88, p65, C-Caspase 3 and Bax expression and increased IKB-α, HO-1, SOD-2 and Bcl-2 expression compared to that in the I/R group. Furthermore, the combination of the two strategies had synergistic anti-inflammatory effects and antioxidant benefits, ultimately limiting neuronal apoptosis. Conclusion: The ‘cocktail’ strategy exhibited a significant neuroprotection against I/RI by attenuating neuroinflammation via inhibition of the TLR4/MyD88/NF-κB signaling pathway.

show abstract

“…10 A recent study demonstrated that alpha-lipoic acid may protect against ischemia-reperfusion injury in patients undergoing kidney and pancreatic transplant. 11 We also used alpha-lipoic acid and observed no adverse effects in 8 patients who had undergone renal transplant.…”

Section: Discussionmentioning

confidence: 99%

Prevalence and Treatment of Neuropathic Pain in Kidney and Liver Transplant Recipients

Öcal

Tanoğlu²,

Kibaroğlu³

et al. 2017

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Neurologic complications are common after kidney and liver transplant. Neurologic complications affect mortality and morbidity in transplant recipients, and neuropathic pain is an important symptom affecting a patient's quality of life. The aim of the present study was to provide readers with our experience regarding causes and treatment of neuropathic pain in patients undergoing kidney and liver transplant at our transplantation center. Materials and Methods:The medical data of 553 kidney transplant recipients and 258 liver transplant recipients who received transplant procedures at the Başkent University Transplantation Center between 2008 and May 2016 were retrospectively reviewed. Fifty-one patients who were examined by an expert neurologist and diagnosed with neuropathic pain on the basis of clinical, neurologic examination, and laboratory findings were included for analyses. Results: Among 811 transplant recipients, 51 patients (6.2%) were diagnosed with neuropathic pain. Of these, 22 were female and 38 were male patients, and 42 were kidney transplant recipients and 9 were liver transplant recipients. Causes of neuropathic pain included uremia, diabetes mellitus, ischemic peripheral arterial disease, inflammatory neuropathy, vasculitis, discopathy, postherpetic neuralgia, carpal tunnel syndrome, and multiple myeloma. Patients with symptoms too mild to affect daily life activities were treated conservatively. Plasmapheresis, gabapentin, pregabalin, alpha-lipoic acid, and duloxetine were administered as treatment modalities and medications.Conclusions: Neuropathic pain was lower in our transplant recipients than in the general population. Treatment medications were effective for transplant recipients at lower doses for the management of neuropathic pain impairing quality of life than doses for the general population.

show abstract

α-Lipoic Acid Protects Against Ischemia-Reperfusion Injury in Simultaneous Kidney-Pancreas Transplantation

Abstract: These results show that ALA preconditioning is capable of reducing inflammatory markers while decreasing early kidney dysfunction and clinical posttransplant pancreatitis.

Cited by 43 publications

References 38 publications

α-lipoic acid reduces postreperfusion syndrome in human liver transplantation - a pilot study

α-lipoic acid reduces postreperfusion syndrome in human liver transplantation - a pilot study

Alpha-Lipoic Acid Preconditioning and Ischaemic Postconditioning Synergistically Protect Rats from Cerebral Injury Induced by Ischemia and Reperfusion Partly via Inhibition TLR4/MyD88/ NF-κB Signaling Pathway

Prevalence and Treatment of Neuropathic Pain in Kidney and Liver Transplant Recipients

Contact Info

Product

Resources

About